All posts by: Michael Zand

About Michael Zand

HealthWatch: A New Gene Therapy For Leukemia; A Study On … – CBS Boston / WBZ

Continue reading

2017-08-30 NEWS

CBS Boston / WBZ

HealthWatch: A New Gene Therapy For Leukemia; A Study On …
CBS Boston / WBZ
A so-called “living drug” that is providing new hope for some kids with cancer. The FDA has just approved CAR-T cell therapy that genetically engineers a …

and more »

Continue reading

2017-08-30 NEWS

NPR

FDA clears first gene-altering therapy — ‘a living drug’ — for childhood leukemia
Washington Post
Unlike some experimental gene approaches, the Novartis treatment, called CAR T-cell therapy, doesn’t replace disease-causing genes with healthy ones. Instead, in a complicated and personalized process, white blood cells called T cells are extracted
FDA Approves First Gene Therapy For LeukemiaNPR
Novartis Sets a Price of $475000 for CAR T-Cell TherapyOncLive
FDA approval brings first gene therapy to the United StatesFDA.gov
Science Magazine –Markets Insider –National Cancer Institute
all 656 news articles »
Continue reading

2017-08-30 NEWS

The Yucatan Times

University of Yucatan launches stem cell laboratory
The Yucatan Times
MERIDA — The Faculty of Dentistry of the Autonomous University of Yucatan (UADY, for its acronym in Spanish) has inaugurated its Translational Cell Laboratory, the only one of its kind in the southeast of the country, where research will be carried

Continue reading

2017-08-30 NEWS

KUNC

FDA Approves First Gene Therapy For Leukemia
KUNC
The Food and Drug Administration on Wednesday announced what the agency calls a “historic action” — the first approval of a cell-based gene therapy in the United States. The FDA approved Kymriah, which scientists refer to as a “living drug” because it …
FDA approval brings first gene therapy to the United StatesFDA.gov
Ben Taub Hospital – Harris Health SystemHarris Health System
‘This Is Surreal’: Houston Dialysis Center Struggles To Treat PatientsNPR
NPR –National Cancer Institute
all 34 news articles »
Continue reading

2017-08-30 NEWS

OncLive

Novartis Sets a Price of $475000 for CAR T-Cell Therapy
OncLive
Novartis’ just-approved chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (Kymriah) is going to be introduced on the market at a price of $475,000 for a single infusion, an amount that is within the range anticipated by oncologists and
First CAR T-Cell ‘Living Drug’ Approved by FDAMedscape
FDA Approves First Gene Therapy For LeukemiaNPR
FDA approves a ‘historic’ new type of leukemia treatmentToday.com
MedPage Today –Scientific American –FDA.gov
all 232 news articles »
Continue reading

2017-08-30 NEWS

Express.co.uk

Cancer breakthrough: Scientists hail gene therapy treatment which KILLS cancer cells
Express.co.uk
CAR-T cell treatment is the first gene therapy to be made available and one of a wave of expensive custom-made “living drugs” being tested against blood cancers. The US Food and Drug Administration agency has hailed its approval as historic.

Continue reading

2017-08-30 NEWS

Wall Street Journal (subscription)

FDA Approves Pioneering Cancer Treatment With $475000 Price Tag
Wall Street Journal (subscription)
The Food and Drug Administration approved a first-of-its kind cancer therapy aimed at bolstering a patient’s own immune cells, while the drugmaker behind the treatment attempted to allay worry over the high cost of the procedure. Swiss pharmaceuticals